Amarin names Adam Berger and Geraldine Murphy to board

Lars Ekman and Patrick O’Sullivan will retire from the Amarin Board of Directors at the end of the year

New independent directors bring significant international experience in healthcare and finance

Seventy-five percent of new independent directors appointed in the last twelve months

Amarin continues active board refresh program

DUBLIN, Ireland and BRIDGEWATER, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Adam Berger and Geraldine Murphy as independent members of the Board of administration of the company, with immediate effect. The company also announced that, in connection with their planned retirements, Lars Ekman, MD, Ph.D and Patrick O’Sullivan, directors of Amarin since 2008 and 2011, respectively, will step down from the board, effective of the end of the year. . With these changes, Amarin’s board will remain comprised of eight directors, seven of whom are independent and five were appointed over the past year as part of the board renewal process which aims to add international experience to support the company’s global expansion efforts.

“We are delighted to appoint two highly respected, results-driven leaders with proven track records in healthcare and finance,” said Per Wold-Olsen, Chairman of Amarin’s Board of Directors. “Today’s appointments represent further progress in our ongoing board refresh program, which advances the collective expertise of our board and ensures we have the right skills to support Amarin’s new strategic priorities. As Amarin continues to refocus and execute its global strategic plan, we are confident that Geraldine and Adam will bring important insights and expertise that will add significant value to the company as we work to drive value for the shareholders.

Mr. Wold-Olsen continued: “On behalf of the entire Board of Directors, I would also like to express our deepest gratitude to Lars and Paddy for their leadership, tenure and dedication to the Amarin Board. . We thank them for their significant contributions to Amarin over the years.”

Mr. Berger has over three decades of experience in M&A-focused investment banking. He has advised over 180 announced M&A transactions, primarily in the healthcare sector, totaling over $400 billion in value and has significant experience in capital markets transactions and value creation for investors. company shareholders. Mr. Berger also brings a unique perspective and skill set as former Chairman of Wells Fargo’s Investment Banking Opinion Committee.

Ms. Murphy brings over 30 years of experience as a healthcare company executive in key business areas including manufacturing, supply chain, profit and loss management and business strategy. . Ms. Murphy has a strong focus on people and organizational development, which will be of great value to Amarin and the Amarin Board.

About Adam Berger

Mr. Berger is currently the Managing Partner of Three Peaks Partners, where he provides financial advisory services to healthcare companies. Mr. Berger has advised on a wide range of corporate mergers and acquisitions, including domestic and international healthcare transactions. He has worked with and advised CEOs, Boards of Directors and Board Committees on various aspects of deals, including deal strategy and tactics, deal structure, terms and business exploration. strategic alternatives.

Prior to Three Peaks Partners, Mr. Berger was Managing Director and Head of Healthcare M&A at Wells Fargo Securities. He also served as chairman of Wells Fargo’s investment banking opinion committee, leading a group of senior M&A bankers to review the firm’s most sensitive M&A transactions, including determining corporate valuation policies and guidelines and evaluating the potential issuance of fairness opinions.

Prior to joining Wells Fargo in 2011, Mr. Berger led the healthcare M&A effort at Citigroup and led Leerink’s M&A group, having worked for many years at the Salomon Brothers mergers and acquisitions group. Mr. Berger has advised many leading companies in the healthcare sector.

About Geraldine Murphy

Ms Murphy – an Irish national – is currently a founder and managing partner of Evolution-Partners, where she provides strategic advice to management teams as they evolve through times of significant transformation and change to support revenue growth and profits. Ms. Murphy is an accomplished biopharmaceutical industry leader with a demonstrated ability to deliver exceptional results in complex and highly regulated environments. She has over 30 years of pharmaceutical leadership experience in key business areas including manufacturing, supply chain, profit and loss management, business strategy development and business transformation.

With a background in science and business and a deep understanding of governance and regulatory environments in the pharmaceutical sector, Ms. Murphy has demonstrated strong collaboration and influencing skills by participating in large-scale pan-European projects requiring a consensus and alignment among multiple stakeholders. Ms. Murphy has led international operations in the UK, Europe, Canada and Australia, delivering significant revenue and profit growth while building key partnerships with regulatory stakeholders, customers and employees. Ms Murphy is a former member of the Irish Pharmaceutical Healthcare Association (2009-2012) and the negotiating team that secured a landmark 4 year supply agreement with the Department of Health. She is a former member of the Association of British Pharmaceutical Industries (ABPI) DoH Supply Agreement Reference Group (2013).

About Amarin

Amarin is an innovative pharmaceutical company at the forefront of a new paradigm in the management of cardiovascular disease. From our scientific research base, to our focus on clinical trials, and now to our global business expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the USA, Dublin in Ireland, Zug in Switzerland and other countries in Europe, as well as business partners and suppliers worldwide. We are committed to rethinking cardiovascular risk by advancing scientific understanding of the societal impact of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

Availability of other information about Amarin

Amarin communicates with its investors and the public using the company’s website (www.amarincorp.com) and the Investor Relations website (investor.amarincorp.com), including, but not limited to, investor presentations and FAQs, Securities and Exchange Commission (“SEC”) filings, press releases, public conference calls and webcasts. Information posted by Amarin on these channels and websites could be considered material information. Accordingly, Amarin encourages investors, the media and others interested in Amarin to regularly review the information posted on these channels, including the Investor Relations website. This list of channels may be updated from time to time on the Amarin Investor Relations website and may include social media channels. The contents of Amarin’s website or such channels, or any other website accessible from its website or such channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-looking statements

This press release contains forward-looking statements within the meaning of United States securities laws. These forward-looking statements are neither promises nor guarantees and involve substantial risks and uncertainties. A list and description of such risks, uncertainties and other risks associated with an investment in Amarin may be found in Amarin’s filings with the SEC, including Amarin’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date to which they are made. Amarin undertakes no obligation to update or revise any information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of material transactions that the company may enter into, such as mergers, acquisitions, divestitures, joint ventures or any material agreements that Amarin may enter into, modify or terminate.

Amarin coordinates

Investor requests:
Investor Relations Amarin Corporation plc
[email protected]

Media inquiries:
Corporate Communications, Amarin Corporation plc
[email protected]

Where

Matt Sherman/Steve Frankel/Tali Epstein
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Comments are closed.